Clinical Trials
18 trialsNCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06607458 2026-03-13
DEL-LIVER
Delcath Systems Inc.
Phase 2 Recruiting
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT04150042 2026-01-29
SHARON
General Oncology, Inc.
Phase 1 Recruiting
NCT01505569 2024-02-26
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT00019760 2023-10-31
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03073694 2023-06-09
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
University of Kansas Medical Center
Phase 2 Unknown
NCT02415036 2022-10-17
Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
Delcath Systems Inc.
Phase 2 Terminated
NCT00623077 2017-12-05
MT2004-30: Tomotherapy for Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00003926 2017-11-29
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00030082 2015-04-30
Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT00103298 2013-06-20
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00089401 2012-05-14
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00019786 2012-03-23
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00020501 2012-03-08
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00001576 2008-03-04
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00001587 2008-03-04
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
National Institutes of Health Clinical Center (CC)
Phase 1 Completed